Phenotypic Manifestations of Hereditary ATTR Amyloidosis
Recruiting
Observational Study
Hereditary Amyloidosis, Transthyretin-Related
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 57 (estimated)
- Sponsor
- Hospital 9 de Julio de Las Breñas · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All subjects between 20 and 70 years of age, carriers of the Val50Met variant
Exclusion Criteria:
* Patients who refuse to participate.
Contacts